SmarterDividends
CUVL

Clinuvel Pharmaceuticals Limited

CUVL

Healthcare · Biotechnology · Stock · annual payer

$5.24

Undervalued · +133% Add to Portfolio

Forward Yield

0.68%

Annual Dividend

$0.04

Payout Ratio

8%

5-Yr Growth

—

Ex-Date

Sep 8, 2026

Frequency

Annual

Key facts about CUVL's dividend

Data as of · Source: SmarterDividends data

  • As of Oct 18, 2026, Clinuvel Pharmaceuticals Limited (CUVL) has a forward dividend yield of 0.68%, based on an annual dividend of $0.04 per share and a share price of $5.24.
  • As of Oct 18, 2026, CUVL's dividend safety grade from SmarterDividends is B (69 out of 100), which rates the dividend as safe.
  • By SmarterDividends' count, Clinuvel Pharmaceuticals Limited (CUVL) has raised its dividend for 3 consecutive years as of Oct 18, 2026.
  • CUVL has never cut its regular dividend in the payment history SmarterDividends has on record.
  • CUVL's most recent ex-dividend date was Sep 8, 2026, for a dividend of $0.0360 per share.
  • As of Oct 18, 2026, CUVL pays out 8% of its trailing 12-month earnings as dividends (its payout ratio).
  • As of Oct 18, 2026, CUVL's 0.68% yield is 200% above its five-year average yield of 0.23%.
  • As of Oct 18, 2026, SmarterDividends' blended fair-value estimate for CUVL is $12.19 per share, 133% above the $5.24 share price, so CUVL screens as undervalued.
  • Clinuvel Pharmaceuticals Limited (CUVL) pays its dividend annual, once a year.
Cite this page

SmarterDividends, "CUVL Dividend: Yield, Safety Grade & Next Ex-Date," updated Oct 18, 2026, https://smarterdividends.com/stocks/CUVL

Summary

As of Oct 18, 2026, Clinuvel Pharmaceuticals Limited (CUVL) yields 0.68% ($0.04 a year per share), has a dividend safety grade of B (69/100) and has 3 consecutive years of dividend increases on record.

Is CUVL a good dividend stock?

Yes, with caveats

Clinuvel Pharmaceuticals Limited (CUVL) pays a annual dividend yielding 0.68% ($0.04/yr), with 3 years of growth and a dividend-safety grade of B. It's a solid income payer, but check the caveats below before buying.

Advantages

  • Never cut its dividend on record
  • Comfortable payout ratio (8%)

Risks

  • Share price is down over the past 5 years

Key Data

Dividend Yield
0.68%
Payout Ratio
8%
Annual Dividend
$0.04
5-Yr Avg Growth
—
Ex-Dividend Date
Sep 8, 2026
Years of Growth
3
Frequency
annual
Beta
0.58
Market Cap
$264.3M
P/E Ratio
11.6
5-Yr Total Return
-74%
52-Week Range
$4.91 – $8.92
Dividend Safety
B · 69/100
Ever Cut?
No

CUVL dividend changes

Clinuvel Pharmaceuticals Limited (CUVL) pays a variable dividend: across the 8 payments on record since 2018, 6 were higher than the one before and 0 lower. The latest change was up 5.9% to $0.0360 per share, going ex-dividend on Sep 8, 2026.

Ex-dateChangeOld → newMove
Sep 8, 2026Higher$0.0340 → $0.0360+5.9%
Sep 9, 2024Higher$0.0320 → $0.0340+6.3%
Sep 7, 2023Higher$0.0270 → $0.0320+18.5%
Sep 9, 2022Higher$0.0180 → $0.0270+50.0%
Sep 4, 2020Higher$0.0170 → $0.0180+5.9%
Sep 6, 2019Higher$0.0140 → $0.0170+21.4%
CUVL ex-dividend date & scheduleNext ex-date Sep 8, 2026 · full ex-dividend historyView →CUVL dividend historyEvery payment, totals by year, raises and cutsView →

Frequently Asked Questions

Is CUVL a good dividend stock?

Yes, with caveats. Clinuvel Pharmaceuticals Limited (CUVL) pays a annual dividend yielding 0.68% ($0.04/yr), with 3 years of growth and a dividend-safety grade of B. It's a solid income payer, but check the caveats below before buying.

Is CUVL undervalued?

Based on a blend of discounted cash flow, a dividend-discount model and an earnings-multiple estimate, CUVL's fair value is about $12.19 versus a $5.24 share price — so it looks undervalued (+133% vs. fair value).

Is CUVL's dividend safe?

CUVL has a dividend-safety grade of B (69/100), based on its payout coverage, free-cash-flow, 3-year growth streak, a clean no-cut history, debt and yield-versus-history.

What is CUVL's fair value?

Our blended fair-value estimate for CUVL is about $12.19 per share, roughly 133% above the current $5.24 price — combining a discounted cash flow, a dividend-discount model and an earnings multiple.

Is CUVL a buy, hold, or sell?

We don't issue formal ratings, but on the data CUVL screens as "yes, with caveats" and undervalued. Clinuvel Pharmaceuticals Limited (CUVL) pays a annual dividend yielding 0.68% ($0.04/yr), with 3 years of growth and a dividend-safety grade of B. It's a solid income payer, but check the caveats below before buying. This is research for your own analysis, not investment advice.

Will CUVL cut its dividend?

CUVL earns a dividend-safety grade of B (69/100), with no dividend cut on record. A higher score means lower cut risk based on payout coverage, cash flow and history — but no score guarantees a dividend.

Does CUVL pay a dividend?

Yes. Clinuvel Pharmaceuticals Limited pays a annual dividend of about $0.04 per share annually, a forward yield of roughly 0.68%.

What is CUVL's dividend yield?

As of Oct 18, 2026, CUVL's forward dividend yield is 0.68%, based on a $0.04 annual dividend and a $5.24 share price.

What is CUVL's dividend per share?

As of Oct 18, 2026, CUVL pays $0.04 per share per year, distributed on a annual basis.

What is CUVL's dividend payout ratio?

As of Oct 18, 2026, CUVL's payout ratio is 8% of trailing 12-month earnings — a comfortable level that leaves room to keep raising the dividend.

How many years has CUVL grown its dividend?

As of Oct 18, 2026, CUVL has increased its dividend for 3 consecutive years.

When is the next CUVL ex-dividend date?

As of Oct 18, 2026, CUVL's next ex-dividend date hasn't been announced. The most recent was Sep 8, 2026, for $0.0360 per share.